Caris Life Sciences (CAI) Change in Accured Expenses (2024 - 2026)

Caris Life Sciences' Change in Accured Expenses history runs 3 years deep, the most recent figure standing at -$15.0 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 680.5% year-over-year to -$15.0 million; the TTM figure through Mar 2026 stood at -$6.1 million (changed N/A YoY), while the FY2025 annual figure was $11.5 million, up 1329.51% from the prior year.
• Change in Accured Expenses was -$15.0 million for Q1 2026 at Caris Life Sciences, down from $29.3 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $29.3 million in Q4 2025 to a low of -$21.3 million in Q2 2025.
• Historically, Change in Accured Expenses has averaged -$732000.0 across 3 years, with a median of $889000.0 in 2025.
• The sharpest annual moves came in 2025 and 2026: Change in Accured Expenses surged 105.4% in 2025, then sank 680.5% in 2026.
• A 3-year view of Change in Accured Expenses shows it stood at $14.8 million in 2024, then surged by 97.46% to $29.3 million in 2025, then plunged by 151.17% to -$15.0 million in 2026.
• The last three Change in Accured Expenses figures came in at -$15.0 million (Q1 2026), $29.3 million (Q4 2025), and $889000.0 (Q3 2025), per Business Quant data.